Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Young, J. H.
Right arrow Articles by Coresh, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Young, J. H.
Right arrow Articles by Coresh, J.
J Am Soc Nephrol 13:2776-2782, 2002
© 2002 American Society of Nephrology

Blood Pressure and Decline in Kidney Function: Findings from the Systolic Hypertension in the Elderly Program (SHEP)

J. Hunter Young*, Michael J. Klag*,{dagger},{ddagger}, Paul Muntner, Joanna L. Whyte||, Marco Pahor& and Josef Coresh*,{dagger},§

Departments of *Medicine, {dagger}Epidemiology, {ddagger}Health Policy and Management, and §Biostatistics, The Johns Hopkins University School of Medicine and The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana; ||Bristol-Myers Squibb, Princeton, New Jersey; and &Department of Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.

Correspondence to: Dr. J. Hunter Young, 2024 East Monument Street, RM 2-612, Baltimore, MD 21205. Phone: 410-502-5808; Fax: 410-614-0476; E-mail: jhyoung{at}jhmi.edu


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
ABSTRACT. The association between BP and decline in kidney function in older persons and the BP component most responsible for kidney disease are unknown. This study investigated the relationship between baseline BP and an incident decline in kidney function among 2181 men and women enrolled in the placebo arm of the Systolic Hypertension in the Elderly Program (SHEP). A decline in kidney function was defined as an increase in serum creatinine equal to or greater than 0.4 mg/dl over 5 yr of follow-up. The incidence and relative risk of a decline in kidney function increased at higher levels of BP for all BP components, independent of age, gender, ethnicity, smoking, diabetes, and history of cardiovascular disease. Systolic BP imparted the highest risk of decline in kidney function. The adjusted relative risk (95% confidence interval) associated with the highest compared with the lowest quartile of BP was 2.44 (1.67 to 3.56) for systolic; 1.29 (0.87 to 1.91) for diastolic; 1.80 (1.21 to 2.66) for pulse; and 2.03 (1.39 to 2.94) for mean arterial pressure. The risk associated with systolic BP remained strong in models containing other BP components, while diastolic, pulse, and mean arterial pressure had no significant association with a decline in kidney function in models containing systolic BP. Therefore, systolic BP is a strong, independent predictor of a decline in kidney function among older persons with isolated systolic hypertension.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Kidney disease is a major public health problem in the United States. The number of persons with treated end-stage renal disease (ESRD) has increased substantially during the past 20 yr (1). This growth has occurred primarily in individuals older than 65 yr of age (1). Moreover, ESRD represents a small portion of the kidney disease burden. For every person with ESRD, 29 people have an elevated serum creatinine (2). Kidney dysfunction is especially common among older persons, affecting 10 to 15% of persons older than 70 yr of age (3).

Efforts to reduce the burden of kidney disease require an understanding of kidney disease risk factors. Elevated BP is a strong independent risk factor for developing ESRD (4,5). However, the association between BP and milder forms of kidney dysfunction is not clear. In addition, the component of BP most responsible for kidney disease is unknown. A growing body of work suggests that, among older persons, systolic BP, and possibly pulse pressure, are more strongly correlated with coronary heart disease, congestive heart failure, and mortality than diastolic BP or mean arterial pressure (6–13). The relative association of each BP component with kidney dysfunction has not been examined.

To determine the risk of a decline in kidney function associated with BP among older men and women, we prospectively studied 2181 people enrolled in the placebo arm of the Systolic Hypertension in the Elderly Program (SHEP). To determine which BP component carries the greatest risk of an incident decline in kidney function, we compared the effects of four different BP measures: systolic pressure, diastolic pressure, pulse pressure, and mean arterial pressure.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
SHEP was a randomized, sixteen-center, hypertension treatment trial designed to study the effect of stepped care beginning with the thiazide diuretic chlorthalidone on stroke incidence among older persons with isolated systolic hypertension (14). Between March 1984 and January 1988, 4736 men and women over the age of 65 yr were randomized. Those undergoing screening were eligible for recruitment when the average of four seated BP measurements, two at each of two baseline visits, was between 160 and 219 mmHg for systolic BP and less than 90 mmHg for diastolic BP. The exclusion criteria included the presence of a major illness, such as a recent myocardial infarction or stroke, cancer, alcoholic liver disease, insulin-treated diabetes mellitus, depression, and kidney failure. Details concerning the screening and recruitment procedures in SHEP have been published elsewhere (14). For this analysis, persons with a serum creatinine greater than 2.0 mg/dl or with serum creatinine measured after randomization were excluded, leaving 4425 participants. To characterize the natural history of the relationship between BP and decline in kidney function, only the 2181 participants randomized to placebo were included in this analysis.

Measurement
Certified technicians using a random-zero sphygmomanometer assessed each participant’s BP. For the current analysis, the baseline systolic BP and diastolic BP were defined as the average of the four baseline BP. Pulse pressure was defined as the systolic BP minus the diastolic BP. Mean arterial pressure was calculated as ([diastolic BP x 2] + systolic BP) ÷ 3.

Outcome
The principal outcome examined in this analysis was incidence of a decline in kidney function, defined as an increase in follow-up creatinine compared with baseline >=0.4 mg/dl. Baseline creatinine was measured at the second baseline visit before randomization. Participants who had previously taken antihypertensive medication were observed off their medication for greater than 2 wk before phlebotomy. Serum creatinine was measured yearly thereafter.

A cutpoint of 0.4 mg/dl change in serum creatinine was chosen as the outcome on the basis of an assessment of the year-to-year variability of serum creatinine among SHEP participants. The SD of change in creatinine between yearly visits was approximately 0.2 mg/dl. Therefore, we defined an incident rise in serum creatinine as a change equal to twice this amount, 0.4 mg/dl. To make certain that any observed associations were insensitive to outcome categorization, separate analyses were performed using other outcomes: mean change in serum creatinine, calculated GFR, and increases in serum creatinine of >=0.5, >=0.6, and >=0.7 mg/dl during follow-up (i.e., more stringent definitions of kidney dysfunction).

Statistical Analyses
Baseline characteristics of the study population were examined overall and by systolic BP quartiles using Kruskal-Wallis tests for continuous variables and {chi}2 tests for categorical variables. The unadjusted incidence of a decline in kidney function per 1000 person-yr of observation was calculated by quartile of BP components using Poisson regression (15). For this calculation, the numerator represents the number of events occurring over the duration of the study; the denominator represents the total number of years of observation. For example, a person who develops kidney dysfunction in year 2 contributes an event to the numerator and 2 yr to the denominator. A person who develops kidney dysfunction in year 5, however, contributes an event to the numerator and 5 yr to the denominator. Therefore, an early event is weighted more heavily than a later event. A second advantage is that people who were lost to follow-up only contribute the time before withdrawal to the denominator. For example, a person lost to follow-up after 3 yr contributes only 3 yr to the denominator.

The relative risk of a decline in kidney function associated with quartiles of BP components was estimated using proportional hazards regression with and without adjustment for age, gender, ethnicity, current smoking status, history of diabetes, and cardiovascular disease (16). Inclusion of body mass index and HDL did not substantially alter risk estimates, so these models are not presented.

The relative predictive power of BP components was also evaluated in two ways. First, because the component measures of BP have different distributions, we calculated the risk associated with a 1 SD difference at baseline in each component. Second, we constructed a series of six models, including every combination of two BP components. To further examine the collinearity between systolic BP and pulse pressure, we then constructed two models using both components after the method used by Franklin et al. (8) In the first model, systolic BP was grouped into quartiles and the effect of pulse pressure was examined within each quartile. In the second model, pulse pressure was grouped into quartiles and the effect of systolic BP was examined within each quartile. Models were compared using likelihood ratio {chi}2.

Antihypertensive medication can affect serum creatinine level. Therefore, we performed an analysis stratified by use of antihypertensive medication before recruitment. In addition, we performed a separate analysis stratified by use of open-label antihypertensive medications during follow-up.

Because kidney disease can increase BP, we also performed an analysis stratified by baseline creatinine to minimize the possibility of reverse causation contributing to the relationship between BP and a subsequent decline in kidney function. Finally, the relative risk of a decline in kidney function was calculated according to quartiles of systolic BP across strata defined by ethnicity and diabetes status at baseline.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
The baseline characteristics of the 2181 SHEP participants are shown by quartile of systolic BP in Table 1. Participants with higher systolic BP tended to be older, were more often women, and had higher diastolic BP, pulse pressure, and mean arterial pressure. Their mean heart rate, however, was lower. Other characteristics did not differ substantially among the systolic BP quartiles.


View this table:
[in this window]
[in a new window]

  		Table 1. Baseline characteristics, overall, and by systolic BP quartile among 2181 SHEP participants
 
Over the 5 yr of follow-up, 226 persons experienced an increase in serum creatinine >=0.4 mg/dl. The unadjusted incidence and adjusted relative risk of a decline in kidney function increased at higher levels of BP for all BP components, but this trend was not statistically significant for diastolic pressure (Table 2 and Figure 1). The risk associated with the highest quartile of BP compared with the lowest was greatest for systolic BP and lowest for diastolic BP (Figure 1). Mean arterial pressure and pulse pressure conveyed intermediate risk. Relative risks were unchanged in unadjusted analyses and in models stratified by gender (data not shown).


View this table:
[in this window]
[in a new window]

  		Table 2. Incidence per 1000 person-yr (95% confidence interval) of a decline in kidney function according to quartiles of BP components among 2181 SHEP participants
 


View larger version (31K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Figure 1. Adjusted relative risk of a decline in kidney function according to quartiles of BP components among 2181 SHEP participants.

 
To compare the relative predictive power of the BP components, we calculated the risk of a decline in kidney function associated with a 1 SD difference in each component at baseline, adjusted for other variables (Table 3). Consistent with the prior analysis, systolic BP conveyed the greatest risk and diastolic BP the lowest. Mean arterial pressure and pulse pressure conveyed intermediate risks.


View this table:
[in this window]
[in a new window]

  		Table 3. Adjusted relative risk (95% confidence interval) of a decline in kidney function associated with a 1 SD higher BPa
 
Because systolic BP, diastolic BP, pulse pressure, and mean arterial pressure are correlated, we constructed joint models consisting of two BP measures. The strong and significant relationship between systolic BP and a decline in kidney function was relatively unchanged when systolic pressure was considered with the other components (relative risks per 1 SD higher systolic BP, 1.35 to 1.42; all P values < 0.001; LR {chi}2 = 46.0, 8 degrees of freedom [df]). In contrast, the risks associated with diastolic, pulse, and mean arterial pressure were reduced and not statistically significant when considered simultaneously with systolic BP (relative risks per 1 SD higher diastolic, pulse, and mean arterial pressure, 1.03, 0.96, and 1.04, respectively; all P values = 0.67; LR {chi}2 = 46.0, 8 df). To further examine the independent effect of systolic BP, we constructed joint models consisting of systolic BP and pulse pressure (Table 4). In the first model, systolic BP was strongly associated with a decline in kidney function, whereas pulse pressure was not. The absence of effect was consistent across strata defined by quartiles of systolic BP. In the second model, pulse pressure was not associated with a decline in kidney function. However, within strata defined by quartiles of pulse pressure, systolic BP was strongly and consistently associated with a decline in kidney function.


View this table:
[in this window]
[in a new window]

  		Table 4. Adjusted relative risk (95% confidence interval) of a decline in kidney function associated with a 1 SD higher BPa
 
Among the models containing a single BP component, the model with systolic BP alone was the most predictive, as evidenced by the high likelihood ratio {chi}2 (LR {chi}2 = 45.8, 7 df, Table 3). The models containing two BP components were not more predictive than the model containing systolic BP alone ({chi}2 = 0.2, 1 df, P = 0.90 for difference between the model containing systolic BP alone and the models containing two BP components).

The association between systolic BP and a decline in kidney function remained strong and graded when more stringent definitions of a decline in kidney function were considered (Table 5). The risk estimates associated with systolic BP were similar when analyses were repeated using mean creatinine change and calculated GFR (data not shown). The use of open-label antihypertensive medication before recruitment or during follow-up did not substantially affect the relationship between baseline systolic BP and an incident decline in kidney function (data not shown).


View this table:
[in this window]
[in a new window]

  		Table 5. Relative risk (95% confidence interval) of a decline in kidney function according to quartiles of systolic BP among 2181 SHEP participantsa
 
Table 6 presents the stratified analyses. The risk of a decline in kidney function associated with systolic BP was strong and graded in all groups and similar in persons with a baseline creatinine below 1.0 mg/dl and those above that cutpoint. The association between systolic BP and a decline in kidney function tended to be greater in persons with diabetes than those without and in African Americans compared with European Americans.


View this table:
[in this window]
[in a new window]

  		Table 6. Stratified relative risk (95% confidence interval) of a decline in kidney function according to quartiles of systolic BP
 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Our study extends knowledge of the link between BP and kidney disease in several ways. Systolic BP, pulse pressure, and mean arterial BP are predictors of decline in kidney function among older persons with isolated systolic hypertension. Adjusting for other factors minimally affected these relationships. Of these measures, systolic BP has the greatest ability to predict a decline in kidney function. In addition, this association persisted in a group with very low likelihood of baseline kidney dysfunction and in high-risk groups, i.e., diabetic patients and African Americans. The risk associated with systolic BP was somewhat greater in these high-risk groups, but there was no statistically significant interaction.

The strong, graded relationship between BP and ESRD is well described (4,5). However, the association between BP and milder forms of kidney disease is less clear. Two longitudinal cohort studies have examined the relationship between baseline BP and decline in kidney function in normotensive population samples. In the Bogalusa Heart Study, baseline BP correlated with an increase in creatinine among young normotensive African-American men but not other race-gender groups (17). In a population sample of middle-aged European Americans, Perneger et al. (18) demonstrated an association between BP and incident hypercreatinemia in both men and women. Similar studies have not been performed in a population sample of older persons. Among hypertensive persons, several studies have demonstrated a decline in kidney function among persons undergoing BP treatment (19,20). In two BP treatment trials, baseline BP was associated with decline in kidney function. In the Hypertension Detection and Follow-up Program, higher baseline diastolic BP was associated with decline in kidney function among middle-aged hypertensive men and women (21,22). In the Multiple Risk Factor Intervention Trial, higher baseline systolic and diastolic BP were associated with decline in kidney function among African-American and European-American men (19). Our results extend these findings to older men and women with isolated systolic hypertension. This association is seen among persons with relatively low levels of creatinine and tended to be more pronounced in persons at higher risk of renal disease, i.e., those with diabetes and African Americans.

The BP component most responsible for kidney disease is unknown. BP varies over the cardiac cycle and is not well characterized by a single measure. Systolic BP is the maximum achieved BP and diastolic BP, the lowest achieved pressure. Mean arterial pressure represents the average pressure, and pulse pressure the variation in BP over a cardiac cycle. As people age, all components increase until midlife, when diastolic pressure begins to fall while systolic and pulse pressure continue to rise (23). With regard to organ damage, components may differ in importance and may damage different organs. Among persons older than 60 yr of age, systolic BP and pulse pressure convey the greatest risk of atherosclerosis and coronary heart disease (6–8,10–13,24). The impact of pulse pressure on cardiac events may be due to the increased cardiac load associated with a high systolic BP and the decreased myocardial perfusion associated with a low diastolic BP (25). However, mean arterial pressure is more closely associated with incident stroke than is pulse pressure (7,25–28). Our results suggest that the risk of a decline in kidney function is more related to systolic BP than pulse pressure, similar to what has been seen for stroke.

This work has several limitations. The sample was limited to older persons with high systolic BP and low diastolic BP. Therefore, we were unable to examine the relationship between BP and kidney dysfunction across the full range of age or BP. In fact, given the absence of a comparison group with normal systolic BP, we likely underestimated the effect of systolic BP on kidney function. In addition, the effect of diastolic BP may be different than that observed given the absence of a group with diastolic BP greater than 90 mmHg. However, these eligibility criteria make this an especially good cohort for examining the effect of pulse pressure. Another limitation is that serum creatinine is an insensitive measure of kidney function, resulting in misclassification of kidney function. Such misclassification would likely create a conservative bias, however, that would lead to underestimating the relative risk. Finally, people at higher risk of events, including decline in kidney function may be more likely to be missing follow-up data (29). This loss to follow-up of high-risk people would likely lead to a conservative bias and subsequent underestimation of risk.

In conclusion, our analysis has shown that systolic BP is a strong independent risk factor for a decline in kidney function among older persons with isolated systolic hypertension. This finding is especially important given that most cases of uncontrolled hypertension in the United States are due to systolic hypertension among older adults (30). Therefore, prevention and treatment of systolic hypertension may help stem the growing epidemic of kidney dysfunction among older persons.


   Acknowledgments
 
Supported by grants T32 DK07732, T32HL07024, R29DK48362, K24DK02856, and AG01760 from the National Institutes of Health and a grant from Bristol-Myers Squibb.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Incidence and prevalence of ESRD. USRDS: United States Renal Data System. Am J Kidney Dis 30: S40–S53, 1997[Medline]
  2. Coresh J, Wei GL, McQuillan G, Brancati FL, Levey AS, Jones C, Klag MJ: Prevalence of high blood pressure and elevated serum creatinine level in the United States: Findings from the third National Health and Nutrition Examination Survey (1988–1994). Arch Intern Med 161: 1207–1216, 2001[Abstract/Free Full Text]
  3. Jones CA, McQuillan GM, Kusek JW, Eberhardt MS, Herman WH, Coresh J, Salive M, Jones CP, Agodoa LY: Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 32: 992–999, 1998[Medline]
  4. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J: Blood pressure and end-stage renal disease in men. N Engl J Med 334: 13–18, 1996[Abstract/Free Full Text]
  5. Perneger TV, Whelton PK, Klag MJ: History of hypertension in patients treated for end-stage renal disease. J Hypertens 15: 451–456, 1997[CrossRef][Medline]
  6. Psaty BM, Furberg CD, Kuller LH, Cushman M, Savage PJ, Levine D, O’Leary DH, Bryan RN, Anderson M, Lumley T: Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: The Cardiovascular Health Study. Arch Intern Med 161: 1183–1192, 2001[Abstract/Free Full Text]
  7. Benetos A, Safar M, Rudnichi A, Smulyan H, Richard JL, Ducimetieere P, Guize L: Pulse pressure: A predictor of long-term cardiovascular mortality in a French male population. Hypertension 30: 1410–1415, 1997[Abstract/Free Full Text]
  8. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D: Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham Heart Study. Circulation 100: 354–360, 1999[Abstract/Free Full Text]
  9. Chae CU, Pfeffer MA, Glynn RJ, Mitchell GF, Taylor JO, Hennekens CH: Increased pulse pressure and risk of heart failure in the elderly. JAMA 281: 634–639, 1999[Abstract/Free Full Text]
  10. Sesso HD, Stampfer MJ, Rosner B, Hennekens CH, Gaziano JM, Manson JE, Glynn RJ: Systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure as predictors of cardiovascular disease risk in Men. Hypertension 36: 801–807, 2000[Abstract/Free Full Text]
  11. Blacher J, Staessen JA, Girerd X, Gasowski J, Thijs L, Liu L, Wang JG, Fagard RH, Safar ME: Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med 160: 1085–1089, 2000[Abstract/Free Full Text]
  12. Glynn RJ, Chae CU, Guralnik JM, Taylor JO, Hennekens CH: Pulse pressure and mortality in older people. Arch Intern Med 160: 2765–2772, 2000[Abstract/Free Full Text]
  13. Vaccarino V, Holford TR, Krumholz HM: Pulse pressure and risk for myocardial infarction and heart failure in the elderly. J Am Coll Cardiol 36: 130–138, 2000[Abstract/Free Full Text]
  14. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 265: 3255–3264, 1991[Abstract]
  15. Armitage P, Berry G: Statistical Methods in Medical Research, 3rd edition, London, England, Blackwell, 1994
  16. Cox DR: Regression models and life tables. J R Stat Soc B 187: 220, 1972
  17. Youssef AA, Srinivasan SR, Elkasabany A, Cruickshank JK, Berenson GS: Temporal relation between blood pressure and serum creatinine in young adults from a biracial community: The Bogalusa Heart Study. Am J Hypertens 13: 770–775, 2000[CrossRef][Medline]
  18. Perneger TV, Nieto FJ, Whelton PK, Klag MJ, Comstock GW, Szklo M: A prospective study of blood pressure and serum creatinine. Results from the ’Clue’ Study and the ARIC Study. JAMA 269: 488–493, 1993[Abstract]
  19. Madhavan S, Stockwell D, Cohen H, Alderman MH: Renal function during antihypertensive treatment. Lancet 345: 749–751, 1995[CrossRef][Medline]
  20. Rostand SG, Brown G, Kirk KA, Rutsky EA, Dustan HP: Renal insufficiency in treated essential hypertension. N Engl J Med 320: 684–688, 1989[Abstract]
  21. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, Schneider KA: Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 13: I80–I93, 1989
  22. Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD: Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JAMA 268: 3085–3091, 1992[Abstract]
  23. Franklin SS, Gustin W, Wong ND, Larson MG, Weber MA, Kannel WB, Levy D: Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 96: 308–315, 1997[Abstract/Free Full Text]
  24. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, Levy D: Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 103: 1245–1249, 2001[Abstract/Free Full Text]
  25. Verdecchia P, Schillaci G, Reboldi G, Franklin SS, Porcellati C: Different prognostic impact of 24-hour mean blood pressure and pulse pressure on stroke and coronary artery disease in essential hypertension. Circulation 103: 2579–2584, 2001[Abstract/Free Full Text]
  26. Domanski MJ, Davis BR, Pfeffer MA, Kastantin M, Mitchell GF: Isolated systolic hypertension: Prognostic information provided by pulse pressure. Hypertension 34: 375–380, 1999[Abstract/Free Full Text]
  27. Millar JA, Lever AF, Burke V: Pulse pressure as a risk factor for cardiovascular events in the MRC Mild Hypertension Trial. J Hypertens 17: 1065–1072, 1999[CrossRef][Medline]
  28. Khattar RS, Swales JD, Banfield A, Dore C, Senior R, Lahiri A: Prediction of coronary and cerebrovascular morbidity and mortality by direct continuous ambulatory blood pressure monitoring in essential hypertension. Circulation 100: 1071–1076, 1999[Abstract/Free Full Text]
  29. Di Bari M, Pahor M, Franse LV, Shorr RI, Wan JY, Ferrucci L, Somes GW, Applegate WB: Dementia and disability outcomes in large hypertension trials: Lessons learned from the systolic hypertension in the elderly program (SHEP) trial. Am J Epidemiol 153: 72–78, 2001[Abstract/Free Full Text]
  30. Hyman DJ, Pavlik VN: Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 345: 479–486, 2001[Abstract/Free Full Text]
Received for publication January 28, 2002. Accepted for publication July 9, 2002.




This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
E. S. Schaeffner, T. Kurth, T. S. Bowman, R. P. Gelber, and J. M. Gaziano
Blood pressure measures and risk of chronic kidney disease in men
Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1246 - 1251.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
R. P. Obermayr, C. Temml, M. Knechtelsdorfer, G. Gutjahr, J. Kletzmayr, S. Heiss, A. Ponholzer, S. Madersbacher, R. Oberbauer, and R. Klauser-Braun
Predictors of new-onset decline in kidney function in a general middle-european population
Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1265 - 1273.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
R. Minutolo, S. Borrelli, R. Scigliano, V. Bellizzi, P. Chiodini, B. Cianciaruso, F. Nappi, P. Zamboli, G. Conte, and L. De Nicola
Prevalence and clinical correlates of white coat hypertension in chronic kidney disease
Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2217 - 2223.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
K. Reynolds, D. Gu, P. Muntner, J. W. Kusek, J. Chen, X. Wu, X. Duan, C.-S. Chen, M. J. Klag, P. K. Whelton, et al.
A Population-Based, Prospective Study of Blood Pressure and Risk for End-Stage Renal Disease in China
J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1928 - 1935.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
A. Shankar, R. Klein, B. E.K. Klein, F. J. Nieto, and S. E. Moss
Relationship Between Low-Normal Blood Pressure and Kidney Disease in Type 1 Diabetes
Hypertension, January 1, 2007; 49(1): 48 - 54.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
N. I. Parikh, S.-J. Hwang, M. G. Larson, J. B. Meigs, D. Levy, and C. S. Fox
Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control.
Arch Intern Med, September 25, 2006; 166(17): 1884 - 1891.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
T. van Bemmel, K. Woittiez, G. J. Blauw, F. van der Sman-de Beer, F. W. Dekker, R. G.J. Westendorp, and J. Gussekloo
Prospective Study of the Effect of Blood Pressure on Renal Function in Old Age: The Leiden 85-Plus Study
J. Am. Soc. Nephrol., September 1, 2006; 17(9): 2561 - 2566.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
W. Palmas, A. Moran, T. Pickering, J. P. Eimicke, J. Teresi, J. E. Schwartz, L. Field, R. S. Weinstock, and S. Shea
Ambulatory Pulse Pressure and Progression of Urinary Albumin Excretion in Older Patients With Type 2 Diabetes Mellitus
Hypertension, August 1, 2006; 48(2): 301 - 308.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
S. T. Turner, S. L.R. Kardia, T. H. Mosley, A. D. Rule, E. Boerwinkle, and M. de Andrade
Influence of Genomic Loci on Measures of Chronic Kidney Disease in Hypertensive Sibships
J. Am. Soc. Nephrol., July 1, 2006; 17(7): 2048 - 2055.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
R. Loutzenhiser, K. Griffin, G. Williamson, and A. Bidani
Renal autoregulation: new perspectives regarding the protective and regulatory roles of the underlying mechanisms
Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2006; 290(5): R1153 - R1167.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
A. M. O'Hare, R. A. Rodriguez, and P. Bacchetti
Low Ankle-Brachial Index Associated With Rise in Creatinine Level Over Time: Results From the Atherosclerosis Risk in Communities Study
Arch Intern Med, July 11, 2005; 165(13): 1481 - 1485.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
C. A. Peralta, L. S. Hicks, G. M. Chertow, J. Z. Ayanian, E. Vittinghoff, F. Lin, and M. G. Shlipak
Control of Hypertension in Adults With Chronic Kidney Disease in the United States
Hypertension, June 1, 2005; 45(6): 1119 - 1124.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
M. Rahman, S. Pressel, B. R. Davis, C. Nwachuku, J. T. Wright Jr, P. K. Whelton, J. Barzilay, V. Batuman, J. H. Eckfeldt, M. Farber, et al.
Renal Outcomes in High-Risk Hypertensive Patients Treated With an Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Blocker vs a Diuretic: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Arch Intern Med, April 25, 2005; 165(8): 936 - 946.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
J. C. Verhave, P. Fesler, G. du Cailar, J. Ribstein, M. E. Safar, and A. Mimran
Elevated Pulse Pressure Is Associated With Low Renal Function in Elderly Patients With Isolated Systolic Hypertension
Hypertension, April 1, 2005; 45(4): 586 - 591.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. Segura, C. Campo, P. Gil, C. Roldan, L. Vigil, J. L. Rodicio, and L. M. Ruilope
Development Of Chronic Kidney Disease and Cardiovascular Prognosis in Essential Hypertensive Patients
J. Am. Soc. Nephrol., June 1, 2004; 15(6): 1616 - 1622.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
C. S. Fox, M. G. Larson, E. P. Leip, B. Culleton, P. W. F. Wilson, and D. Levy
Predictors of New-Onset Kidney Disease in a Community-Based Population
JAMA, February 18, 2004; 291(7): 844 - 850.
[Abstract] [Full Text] [PDF]

Home page
 ANGIOLOGYHome page
F. Youssef, P. Gupta, A. M. Seifalian, F. Myint, D. P. Mikhailidis, and G. Hamilton
The Effect of Short-Term Treatment with Simvastatin on Renal Function in Patients with Peripheral Arterial Disease
Angiology, January 1, 2004; 55(1): 53 - 62.
[Abstract] [PDF]

Home page
 HypertensionHome page
S. Vupputuri, V. Batuman, P. Muntner, L. A. Bazzano, J. J. Lefante, P. K. Whelton, and J. He
Effect of Blood Pressure on Early Decline in Kidney Function Among Hypertensive Men
Hypertension, December 1, 2003; 42(6): 1144 - 1149.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
T. H. Jafar, P. C. Stark, C. H. Schmid, M. Landa, G. Maschio, P. E. de Jong, D. de Zeeuw, S. Shahinfar, R. Toto, A. S. Levey, et al.
Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis
Ann Intern Med, August 19, 2003; 139(4): 244 - 252.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Young, J. H.
Right arrow Articles by Coresh, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Young, J. H.
Right arrow Articles by Coresh, J.

HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP